Insights

Innovative Vaccine Platform Vaxart's proprietary oral vaccine technology targeting mucosal immunity offers a unique differentiation point. This innovative approach can appeal to healthcare providers and governments seeking more effective and patient-friendly immunization options, opening opportunities for partnerships and clinical collaborations.

Expanding Clinical Trials With Phase II trials underway for Covid-19 and Norovirus vaccines, Vaxart is progressing toward advanced stages of development. This creates potential sales opportunities with public health agencies and pharmaceutical companies interested in licensing or distributing these novel oral vaccines.

Focus on Infectious Diseases Vaxart's portfolio includes vaccines for Covid, Norovirus, Influenza, and therapeutic HPV vaccines, demonstrating a broad focus on infectious disease prevention. Companies and health organizations involved in infectious disease control may be interested in adopting or distributing Vaxart's oral vaccines.

Financial and Market Potential Although revenue is currently modest, the company's advancements and participation in major biotech events suggest strong future growth potential. Opportunities exist for business partners to engage through licensing, technology transfer, or co-development agreements to capitalize on emerging market demand for novel vaccines.

Similar companies to Vaxart, Inc.

Vaxart, Inc. Tech Stack

Vaxart, Inc. uses 8 technology products and services including oEmbed, JSON-LD, DataTables, and more. Explore Vaxart, Inc.'s tech stack below.

  • oEmbed
    Dev Tools
  • JSON-LD
    Javascript Frameworks
  • DataTables
    Javascript Libraries
  • New Relic
    Real User Monitoring
  • Yoast SEO
    Search Engines
  • X-XSS-Protection
    Security
  • Cloudflare Bot Management
    Security
  • X-Content-Type-Options
    Web & Portal Technology

Media & News

Vaxart, Inc.'s Email Address Formats

Vaxart, Inc. uses at least 1 format(s):
Vaxart, Inc. Email FormatsExamplePercentage
FLast@vaxart.comJDoe@vaxart.com
49%
FMiddleLast@vaxart.comJMichaelDoe@vaxart.com
1%
FLast@vaxart.comJDoe@vaxart.com
49%
FMiddleLast@vaxart.comJMichaelDoe@vaxart.com
1%

Frequently Asked Questions

What is Vaxart, Inc.'s phone number?

Minus sign iconPlus sign icon
You can contact Vaxart, Inc.'s main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Vaxart, Inc.'s stock symbol?

Minus sign iconPlus sign icon
Vaxart, Inc. is a publicly traded company; the company's stock symbol is VXRT.

What is Vaxart, Inc.'s official website and social media links?

Minus sign iconPlus sign icon
Vaxart, Inc.'s official website is vaxart.com and has social profiles on LinkedInCrunchbase.

What is Vaxart, Inc.'s SIC code NAICS code?

Minus sign iconPlus sign icon
Vaxart, Inc.'s SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Vaxart, Inc. have currently?

Minus sign iconPlus sign icon
As of January 2026, Vaxart, Inc. has approximately 112 employees across 2 continents, including North AmericaEurope. Key team members include Chief Financial Officer Executive Vice President: M. C.Chief Financial Officer: J. H.Chief Technology Officer: R. S.. Explore Vaxart, Inc.'s employee directory with LeadIQ.

What industry does Vaxart, Inc. belong to?

Minus sign iconPlus sign icon
Vaxart, Inc. operates in the Biotechnology Research industry.

What technology does Vaxart, Inc. use?

Minus sign iconPlus sign icon
Vaxart, Inc.'s tech stack includes oEmbedJSON-LDDataTablesNew RelicYoast SEOX-XSS-ProtectionCloudflare Bot ManagementX-Content-Type-Options.

What is Vaxart, Inc.'s email format?

Minus sign iconPlus sign icon
Vaxart, Inc.'s email format typically follows the pattern of FLast@vaxart.com. Find more Vaxart, Inc. email formats with LeadIQ.

When was Vaxart, Inc. founded?

Minus sign iconPlus sign icon
Vaxart, Inc. was founded in 2004.

Vaxart, Inc.

Biotechnology ResearchCalifornia, United States51-200 Employees

For two hundred years vaccines have been administered by intramuscular injection.  Vaxart’s oral vaccine pills may change everything.

Our vaccine pills act differently, by attacking invading pathogens in the places where they first enter the body:  the mucosal areas, including the mouth, the nose and the gut.  They are designed to  trigger strong IgA and T-cell responses to repel and overwhelm the invading viral invaders.

Vaxart has begun Phase II trials of its oral vaccine for Covid and for Norovirus– the only company in the world to reach this stage with a COVID-19 vaccine pill.

Section iconCompany Overview

Phone number
Website
vaxart.com
SIC Code
8733 - Noncommercial Research Organizations
Stock Symbol
VXRT
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2004
Employees
51-200

Section iconFunding & Financials

  • $1M$10M

    Vaxart, Inc.'s revenue is estimated to be in the range of $1M$10M

Section iconFunding & Financials

  • $1M$10M

    Vaxart, Inc.'s revenue is estimated to be in the range of $1M$10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.